Press release

Orexo to present additional data on OX640, a novel nasal epinephrine powder, in two oral presentations at ACAAI 2026

UPPSALA, Sweden – November 10th, 2026 – Orexo AB (publ.) **(STO: ORX) (OTCQX:ORXOY)** today announced that its US subsidiary, Orexo US, Inc., will present two oral abstracts with additional data on OX640, a novel nasal epinephrine powder, at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting, taking place in Phoenix, Arizona, November 12-16, 2026.

Details of Oral Abstracts

"Time to meaningful epinephrine levels of an epinephrine nasal powder in patients with allergic rhinitis"
Date and Time: November 13, 2026, 4:35 PM – 4:50 PM MST
Abstract ID: 8259
ePoster ID: R010
Presenting Author: Anne Ellis, MD, MSc, FACAAI

"Relative stability of epinephrine nasal powder formulations compared to liquid epinephrine formulations"
Date and Time: November 13, 2026, 5:20 PM – 5:35 PM MST
Abstract ID: 8255
ePoster ID: R013
Presenting Author: Edward Kim, MD, MBA

Nikolaj Sørensen, President and CEO of Orexo AB, said: *"We are excited to present data demonstrating rapid achievement of clinically meaningful epinephrine levels for our OX640 intranasal powdered epinephrine. The AmorphOX® platform provides both rapid bioavailability as well as long-term stability even under accelerated aging conditions, both of which are essential properties of emergency rescue products."*

For further information contact:
Nikolaj Sørensen, President and CEO
ir@orexo.com

About OX640

OX640 is a powder-based intranasal formulation of epinephrine in clinical development for the emergency treatment of anaphylaxis. The product is based on Orexo's proprietary AmorphOX®

technology, which enables the formulation of medicines with improved stability and rapid absorption through the nasal mucosa. OX640 is being developed as a needle-free alternative to today's epinephrine autoinjectors.

About Orexo

Orexo is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs. At the core of Orexo's innovation is AmorphOX®, a proprietary drug delivery technology designed to improve bioavailability and stability for both large and small molecules, enabling new approaches to administration, manufacturing, and distribution. With more than 30 years of experience and multiple medicines approved globally, Orexo is advancing a diversified pipeline of programs in clinical and preclinical development. The company collaborates with partners in research, development, and commercialization. Headquartered in Uppsala, Sweden, Orexo is listed on Nasdaq Stockholm's main market and trades as ADRs on the OTCQX market in the United States.

For more information, please visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube.